Understand the source comparison
Peptides for Libido: Mechanism Comparison
PT-141 (Bremelanotide) MC4R (melanocortin-4 receptor) Activates hypothalamic MC4R → dopamine + oxytocin release → increased desire and arousal independent of vascular changes 4–6 hours Female hypoactive sexual desire disorder; psychogenic erectile dysfunction
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- PT-141 (Bremelanotide)
- MC4R (melanocortin-4 receptor)
- Activates hypothalamic MC4R → dopamine + oxytocin release → increased desire and arousal independent of vascular changes
- 4–6 hours
- Female hypoactive sexual desire disorder; psychogenic erectile dysfunction
- Most selective for central sexual arousal without cardiovascular or pigmentation effects. FDA-approved for HSDD
- Melanotan II
- MC3R, MC4R, MC1R
- Non-selective melanocortin agonism → dopaminergic activation + appetite suppression + pigmentation
- 6–8 hours
- Studies examining reward pathway modulation; overlap of feeding and reproductive signaling
- Broader receptor profile produces effects beyond libido. Used primarily in research contexts
- Kisspeptin-10
- GPR54 (kisspeptin receptor)
- Stimulates pulsatile GnRH release → LH/FSH secretion → endogenous testosterone synthesis
- Single dose: 4–6 hours; repeated dosing: sustained HPG axis normalization
- Secondary hypogonadism; fertility research; HPG axis dysfunction
- Restores physiological testosterone production without suppressing endogenous synthesis
- Oxytocin
- Oxytocin receptor (OXTR)
- Enhances pair bonding, trust, and sexual receptivity through limbic system activation
- 2–3 hours (intranasal); variable with peripheral administration
- Social bonding studies; sexual dysfunction with psychological overlay
- Effects are context-dependent. Enhances sexual experience primarily in established relationships